Sermorelin

Sermorelin is a synthetic analogue of the biologically active N-terminal portion of growth-hormone-releasing hormone and is used in research on pituitary GH secretion and endocrine testing.

Agonizes the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth-hormone release.

Historical human evidence and prior approved diagnostic/therapeutic use; current marketed status varies.

Level III, Limited/historical human evidence

Results cannot be generalized to undefined formulations. Endocrine response depends on pituitary function, age, disease state, and assay timing.

Potential effects include flushing, headache, injection-site reactions, edema, glucose changes, and endocrine-axis effects.

Historically FDA-approved products existed; current research preparations are not automatically approved or equivalent.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• Sermorelin, 5 mgLyophilized
• Sermorelin, 15 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.